However, a clinical trial in patients with early‐stage AD found only a slight and highly variable improvement in mini mental state examination scores and no change in cerebrospinal fluid (CSF) levels of tau after 4 weeks of treatment with the antiviral valacyclovir (Weidung et al., 2022). This evidence concerns the gene MAPT and Alzheimer disease.